Published in J Clin Invest on June 23, 2010
Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med (2014) 2.05
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst (2012) 1.81
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med (2012) 1.58
Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice. J Clin Invest (2016) 1.43
New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med (2013) 1.35
Uncoupling p53 functions in radiation-induced intestinal damage via PUMA and p21. Mol Cancer Res (2011) 1.34
Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner. Blood (2014) 1.32
Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov (2015) 1.27
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle (2012) 1.20
RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget (2015) 1.20
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets (2010) 1.10
Runx1 loss minimally impacts long-term hematopoietic stem cells. PLoS One (2011) 1.06
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget (2015) 1.05
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) (2014) 1.05
Targeting cancer with kinase inhibitors. J Clin Invest (2015) 1.05
The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys (2011) 1.04
CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle (2013) 1.04
NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. J Clin Invest (2014) 1.03
Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. Front Oncol (2014) 1.00
Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med (2011) 0.98
Radioprotection: smart games with death. J Clin Invest (2010) 0.98
Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med (2011) 0.95
Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. Hepatology (2011) 0.95
The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis. Cell Cycle (2014) 0.94
Linking traumatic brain injury to chronic traumatic encephalopathy: identification of potential mechanisms leading to neurofibrillary tangle development. J Neurotrauma (2014) 0.93
Ionizing irradiation induces acute haematopoietic syndrome and gastrointestinal syndrome independently in mice. Nat Commun (2014) 0.93
HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS One (2012) 0.93
Intestinal stem cell injury and protection during cancer therapy. Transl Cancer Res (2013) 0.92
ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage. Nucleic Acids Res (2013) 0.91
Activation of Hif1α by the prolylhydroxylase inhibitor dimethyoxalyglycine decreases radiosensitivity. PLoS One (2011) 0.90
CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. Am J Physiol Renal Physiol (2013) 0.89
Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther (2011) 0.88
Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells. Oncotarget (2012) 0.88
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res (2016) 0.87
Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells. Stem Cells (2013) 0.87
Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A (2015) 0.84
Chromatin perturbations during the DNA damage response in higher eukaryotes. DNA Repair (Amst) (2015) 0.84
Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay. Radiat Res (2012) 0.82
Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol (2013) 0.82
An inducible long noncoding RNA amplifies DNA damage signaling. Nat Genet (2016) 0.81
Pleiotrophin mediates hematopoietic regeneration via activation of RAS. J Clin Invest (2014) 0.81
Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.). J Mol Cell Cardiol (2013) 0.81
Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer (2017) 0.81
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol (2016) 0.80
Does CDKN2A loss predict palbociclib benefit? Curr Oncol (2015) 0.80
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res (2015) 0.79
Sodium orthovanadate (vanadate), a potent mitigator of radiation-induced damage to the hematopoietic system in mice. J Radiat Res (2013) 0.79
Catalase inhibits ionizing radiation-induced apoptosis in hematopoietic stem and progenitor cells. Stem Cells Dev (2015) 0.78
Transport processes of radiopharmaceuticals and -modulators. Radiat Oncol (2011) 0.78
The transcription factor E74-like factor controls quiescence of endothelial cells and their resistance to myeloablative treatments in bone marrow. Arterioscler Thromb Vasc Biol (2011) 0.78
Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility. PLoS One (2015) 0.77
Autophagy confers DNA damage repair pathways to protect the hematopoietic system from nuclear radiation injury. Sci Rep (2015) 0.77
Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death. J Pharmacol Exp Ther (2013) 0.76
Enhanced Megakaryopoiesis and Platelet Activity in Hypercholesterolemic, B6-Ldlr-/-, Cdkn2a-Deficient Mice. Circ Cardiovasc Genet (2016) 0.75
Disruption of Notch signaling aggravates irradiation-induced bone marrow injury, which is ameliorated by a soluble Dll1 ligand through Csf2rb2 upregulation. Sci Rep (2016) 0.75
Protracted Oxidative Alterations in the Mechanism of Hematopoietic Acute Radiation Syndrome. Antioxidants (Basel) (2015) 0.75
HSC senescence upon irradiation. Blood (2014) 0.75
mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Mol Cancer Ther (2017) 0.75
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget (2017) 0.75
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell (2005) 24.00
p21 is a universal inhibitor of cyclin kinases. Nature (1993) 15.55
Clonogenic assay of cells in vitro. Nat Protoc (2006) 11.85
Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science (2000) 10.81
A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A (1974) 8.74
p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell (1994) 7.05
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem (1997) 6.99
Living with or without cyclins and cyclin-dependent kinases. Genes Dev (2004) 6.54
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther (2004) 5.69
Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med (2005) 5.68
The comet assay: a method to measure DNA damage in individual cells. Nat Protoc (2006) 5.11
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst (2007) 4.97
An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science (2008) 4.89
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev (1994) 4.64
Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU. Nature (2007) 4.62
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell (2004) 4.39
Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol (2006) 4.20
Single-strand break repair and genetic disease. Nat Rev Genet (2008) 4.07
Radiation response of mammalian cells grown in culture. 1. Repair of X-ray damage in surviving Chinese hamster cells. Radiat Res (1960) 3.54
Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. J Biol Chem (2009) 3.24
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem (2005) 2.88
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47
X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res (1966) 2.35
X-ray damage and recovery in mammalian cells in culture. Nature (1959) 2.30
Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J Clin Invest (2002) 2.22
The restriction point of the cell cycle. Cell Cycle (2002) 2.22
DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene (2003) 2.10
X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science (1963) 1.93
F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature (2009) 1.93
Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res (2003) 1.86
Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci U S A (1997) 1.79
Tip60: connecting chromatin to DNA damage signaling. Cell Cycle (2010) 1.73
History and development of radiation-protective agents. Int J Radiat Biol (2009) 1.68
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res (2007) 1.62
Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev (1997) 1.59
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol (2006) 1.56
Treatment of growing teratoma syndrome. N Engl J Med (2009) 1.43
Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst (1992) 1.41
Repair of sub-lethal and potentially lethal radiation damage in plateau phase cultures of human cells. Nature (1969) 1.33
Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. Cancer Res (2007) 1.32
Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma -irradiation promotes survival. Blood (2002) 1.31
Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene (2003) 1.29
E2F1 mediates DNA damage and apoptosis through HCF-1 and the MLL family of histone methyltransferases. EMBO J (2009) 1.28
Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell (2009) 1.27
Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res (2006) 1.27
Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Res (2005) 1.25
In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice. Blood (1990) 0.99
Revisiting the "Cdk-centric" view of the mammalian cell cycle. Cell Cycle (2005) 0.95
Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem (2003) 0.94
DNA interstrand cross-links induced by ionizing radiation: an unsung lesion. Mutat Res (2010) 0.90
Relationship between chromatin structure, DNA damage and repair following X-irradiation of human lymphocytes. Mutat Res (2010) 0.84
The formation of radiation-induced DNA breaks: the ratio of double-strand breaks to single-strand breaks. Int J Radiat Oncol Biol Phys (1985) 0.84
Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. J Natl Cancer Inst (2000) 0.84
Radioprotection by mitotic inhibitors and mercaptoethylamine. Science (1961) 0.80
Protective effect of a colchicine derivative in mice exposed to x-radiation. Science (1958) 0.77
The importance of G1/S-border and mitosis in the fixation of potentially lethal damage. Radiat Environ Biophys (1983) 0.77
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
The regulation of INK4/ARF in cancer and aging. Cell (2006) 8.75
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Ink4a/Arf expression is a biomarker of aging. J Clin Invest (2004) 8.30
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature (2006) 8.06
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Ancient human genome sequence of an extinct Palaeo-Eskimo. Nature (2010) 7.51
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA (2012) 5.16
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Isoprenoid pathway optimization for Taxol precursor overproduction in Escherichia coli. Science (2010) 4.96
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
An Aboriginal Australian genome reveals separate human dispersals into Asia. Science (2011) 4.84
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science (2006) 4.71
An index of substitution saturation and its application. Mol Phylogenet Evol (2003) 4.71
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet (2010) 3.89
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet (2011) 3.66
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell (2011) 3.58
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature (2011) 3.19
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
Adhesive phase separation at the dentin interface under wet bonding conditions. J Biomed Mater Res (2002) 3.08
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell (2013) 3.04
Arp2/3 is critical for lamellipodia and response to extracellular matrix cues but is dispensable for chemotaxis. Cell (2012) 2.98
Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry (2006) 2.85
Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood (2005) 2.82
INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One (2009) 2.77
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res (2005) 2.72
Manipulating surface states in topological insulator nanoribbons. Nat Nanotechnol (2011) 2.70
Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol (2013) 2.68
Large electrocaloric effect in ferroelectric polymers near room temperature. Science (2008) 2.66
A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol (2002) 2.66
Characterization of the cell of origin for small cell lung cancer. Cell Cycle (2011) 2.62
Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. Circulation (2010) 2.57
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res (2007) 2.45
Autophagic proteins regulate cigarette smoke-induced apoptosis: protective role of heme oxygenase-1. Autophagy (2008) 2.38
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med (2011) 2.35
FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. Blood (2008) 2.31
Relationship of solvent to the photopolymerization process, properties, and structure in model dentin adhesives. J Biomed Mater Res A (2007) 2.26
RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25
Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell (2009) 2.21
The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J Biol Chem (2005) 2.21
Somatic LKB1 mutations promote cervical cancer progression. PLoS One (2009) 2.21
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res (2010) 2.20
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. J Surg Oncol (2006) 2.19
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A (2006) 2.17
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17
Expression of p16(INK4a) prevents cancer and promotes aging in lymphocytes. Blood (2011) 2.16
Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol (2007) 2.16
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res (2010) 2.14
The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene (2004) 2.14
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg Infect Dis (2009) 2.13
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2012) 2.13
Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res (2005) 2.13